ReviewInternational journal of chronic obstructive pulmonary disease2008
Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety.
Review in International journal of chronic obstructive pulmonary disease, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.Advances in therapy · 2019Pooled it
- The Effect of Inhaled Beta-2 Agonists on Heart Rate in Patients With Asthma: Sensor-Based Observational Study.JMIR cardio · 2024Observational
- Challenges and Opportunities in COPD Management in Latin America: A Review of Inhalation Therapies and Advanced Drug Delivery Systems.Pharmaceutics · 2024Review
- Lung Hyperinflation as Treatable Trait in Chronic Obstructive Pulmonary Disease: A Narrative Review.International journal of chronic obstructive pulmonary disease · 2024Review
- The Complex Association between COPD and COVID-19.Journal of clinical medicine · 2023Review
- Health-related quality of life and its associated factors in patients with chronic obstructive pulmonary disease.PloS one · 2023Article
- Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics.Biomedicines · 2022Review
- Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2020Review
- Effects of LAMA/LABA Alone and in Combination on Cardiac Safety.International journal of chronic obstructive pulmonary disease · 2020Article
- Inhaled corticosteroids, blood eosinophils, and FEVInternational journal of chronic obstructive pulmonary disease · 2019Observational
- Targeting Cytokines as Evolving Treatment Strategies in Chronic Inflammatory Airway Diseases.International journal of molecular sciences · 2018Review
- Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2016Article
- Differentiation of human bronchial epithelial cells: role of hydrocortisone in development of ion transport pathways involved in mucociliary clearance.American journal of physiology. Cell physiology · 2016Article
- Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol.Therapeutics and clinical risk management · 2015Review
- Indacaterol: a comprehensive review.International journal of chronic obstructive pulmonary disease · 2013Review
- β(2) -adrenoceptor agonists: current and future direction.British journal of pharmacology · 2011Review
- Nebulized formoterol: a review of clinical efficacy and safety in COPD.International journal of chronic obstructive pulmonary disease · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COPD is characterized by progressive airflow obstruction which does not fully reverse to inhaled or oral pharmacotherapy. The management of patients with COPD has taken a totally new direction over the past 20 years, thank to the use of novel therapies aimed to improve and modify the natural history of COPD. Long-acting bronchodilators, including long-acting beta2-agonists (LABAs), were introduced several years ago in order to enhance improvements in lung function, health status related quality of life, and reduce the rate of exacerbations. These effects can be boosted by the combination of LABAs with long-acting anticholinergic, and/or with inhaled corticosteroids. Inhaled LABAs are commonly well tolerated although adverse effects such as tremor and palpitations are occasionally troublesome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.